Etidronate for treating and preventing postmenopausal osteoporosis

Basic and clinical aspects of osteoporosis in inflammatory bowel disease

“…Risedronate was efficacious, irrespective of underlying disease and duration of corticosteroid therapy, and had a favorable safety profile, with a similar incidence of upper gastrointestinal adverse events to placebo [108,109] . Etidronate have shown to be superior to placebo for increasing BMD in lumbar spine and femoral neck, and reducing incidence of vertebral fractures with no effect in non-vertebral fractures in postmenopausal women [110] . A meta-analysis reported that intermittent cyclical etidronate (400 mg/d for 14 d, followed by 500 mg calcium daily for 76 d) in corticoid treated patients was effective in preventing bone loss, increasing bone mass but with no statistical significance on reduction of fractures [111] .…”

Basic and clinical aspects of osteoporosis in inflammatory bowel disease

“…Risedronate was efficacious, irrespective of underlying disease and duration of corticosteroid therapy, and had a favorable safety profile, with a similar incidence of upper gastrointestinal adverse events to placebo [108,109] . Etidronate have shown to be superior to placebo for increasing BMD in lumbar spine and femoral neck, and reducing incidence of vertebral fractures with no effect in non-vertebral fractures in postmenopausal women [110] . A meta-analysis reported that intermittent cyclical etidronate (400 mg/d for 14 d, followed by 500 mg calcium daily for 76 d) in corticoid treated patients was effective in preventing bone loss, increasing bone mass but with no statistical significance on reduction of fractures [111] .…”

Actualización en el tratamiento de la osteoporosis: manejo desde una unidad del dolor (1.ª parte)

“…El risedronato (Acrel ® , Actonel ® ) 5 mg/día (35 mg semanales) tiene un efecto positivo sobre la DMO y reduce el riesgo de fracturas vertebrales, no vertebrales y de cadera en mujeres con osteoporosis establecida (20). El etidronato (Osteum ® ) fue el primer bifosfonato utilizado en la clínica, es eficaz en la reducción de fracturas vertebrales a 2 años pero no sobre el resto de fracturas; no se recomienda como primera línea de tratamiento (21). La biodisponibilidad oral de los bifosfonatos es baja, entre 1 y 3 % de la dosis ingerida; además su absorción se altera con la comida, calcio, café o zumo de naranja.…”

Quality Indicators for the Care of Osteoporosis in Vulnerable Elders

“…Eleven percent of placebo subjects and 8% of alendronate subjects experienced fractures, which was not statistically different. Routine spine radiographs were not part of the study Bone 118 Alendronate vs premarin vs combination therapy vs placebo RCT Bone density of the lumbar spine was 6.0% greater with alendronate than with placebo, 6.0% greater for conjugated equine estrogens, and 8.3% greater for the combination; no difference in fracture rates 123 Etidronate Meta-analysis The pooled RR of vertebral fracture was 0.60% (95% CI 5 0.41-0.88), but no effect on nonvertebral fractures was seen Harris 124 Etidronate RCT BMD improved, but the risk of vertebral fractures was lower only for those at greater risk, defined as baseline BMD o50th percentile for the study group or three vertebral fractures Heath 125 Etidronate RCT Reduced rate of bone loss with etidronate Tanko 126 Ibandronate RCT 20 mg weekly dose of ibandronate significantly increased BMD at the spine and hip (4.0% and 2.7%, respectively, more than placebo) Chesnut 127 Ibandronate RCT Daily and intermittent oral ibandronate significantly reduced the risk of new vertebral fractures 62% and 50%, respectively, and improved BMD. The incidence of nonvertebral fractures was not different between the three groups Reid 128 Zoledronic acid RCT BMD improvement of the lumbar spine 4.3% to 5.1% compared with placebo (Po.001)…”

Basic and clinical aspects of osteoporosis in inflammatory bowel disease

“…Risedronate was efficacious, irrespective of underlying disease and duration of corticosteroid therapy, and had a favorable safety profile, with a similar incidence of upper gastrointestinal adverse events to placebo [108,109] . Etidronate have shown to be superior to placebo for increasing BMD in lumbar spine and femoral neck, and reducing incidence of vertebral fractures with no effect in non-vertebral fractures in postmenopausal women [110] . A meta-analysis reported that intermittent cyclical etidronate (400 mg/d for 14 d, followed by 500 mg calcium daily for 76 d) in corticoid treated patients was effective in preventing bone loss, increasing bone mass but with no statistical significance on reduction of fractures [111] .…”

Actualización en el tratamiento de la osteoporosis: manejo desde una unidad del dolor (1.ª parte)

“…El risedronato (Acrel ® , Actonel ® ) 5 mg/día (35 mg semanales) tiene un efecto positivo sobre la DMO y reduce el riesgo de fracturas vertebrales, no vertebrales y de cadera en mujeres con osteoporosis establecida (20). El etidronato (Osteum ® ) fue el primer bifosfonato utilizado en la clínica, es eficaz en la reducción de fracturas vertebrales a 2 años pero no sobre el resto de fracturas; no se recomienda como primera línea de tratamiento (21). La biodisponibilidad oral de los bifosfonatos es baja, entre 1 y 3 % de la dosis ingerida; además su absorción se altera con la comida, calcio, café o zumo de naranja.…”

Quality Indicators for the Care of Osteoporosis in Vulnerable Elders

“…Eleven percent of placebo subjects and 8% of alendronate subjects experienced fractures, which was not statistically different. Routine spine radiographs were not part of the study Bone 118 Alendronate vs premarin vs combination therapy vs placebo RCT Bone density of the lumbar spine was 6.0% greater with alendronate than with placebo, 6.0% greater for conjugated equine estrogens, and 8.3% greater for the combination; no difference in fracture rates 123 Etidronate Meta-analysis The pooled RR of vertebral fracture was 0.60% (95% CI 5 0.41-0.88), but no effect on nonvertebral fractures was seen Harris 124 Etidronate RCT BMD improved, but the risk of vertebral fractures was lower only for those at greater risk, defined as baseline BMD o50th percentile for the study group or three vertebral fractures Heath 125 Etidronate RCT Reduced rate of bone loss with etidronate Tanko 126 Ibandronate RCT 20 mg weekly dose of ibandronate significantly increased BMD at the spine and hip (4.0% and 2.7%, respectively, more than placebo) Chesnut 127 Ibandronate RCT Daily and intermittent oral ibandronate significantly reduced the risk of new vertebral fractures 62% and 50%, respectively, and improved BMD. The incidence of nonvertebral fractures was not different between the three groups Reid 128 Zoledronic acid RCT BMD improvement of the lumbar spine 4.3% to 5.1% compared with placebo (Po.001)…”

Basic and clinical aspects of osteoporosis in inflammatory bowel disease

“…Risedronate was efficacious, irrespective of underlying disease and duration of corticosteroid therapy, and had a favorable safety profile, with a similar incidence of upper gastrointestinal adverse events to placebo [108,109] . Etidronate have shown to be superior to placebo for increasing BMD in lumbar spine and femoral neck, and reducing incidence of vertebral fractures with no effect in non-vertebral fractures in postmenopausal women [110] . A meta-analysis reported that intermittent cyclical etidronate (400 mg/d for 14 d, followed by 500 mg calcium daily for 76 d) in corticoid treated patients was effective in preventing bone loss, increasing bone mass but with no statistical significance on reduction of fractures [111] .…”

Actualización en el tratamiento de la osteoporosis: manejo desde una unidad del dolor (1.ª parte)

“…El risedronato (Acrel ® , Actonel ® ) 5 mg/día (35 mg semanales) tiene un efecto positivo sobre la DMO y reduce el riesgo de fracturas vertebrales, no vertebrales y de cadera en mujeres con osteoporosis establecida (20). El etidronato (Osteum ® ) fue el primer bifosfonato utilizado en la clínica, es eficaz en la reducción de fracturas vertebrales a 2 años pero no sobre el resto de fracturas; no se recomienda como primera línea de tratamiento (21). La biodisponibilidad oral de los bifosfonatos es baja, entre 1 y 3 % de la dosis ingerida; además su absorción se altera con la comida, calcio, café o zumo de naranja.…”

Quality Indicators for the Care of Osteoporosis in Vulnerable Elders

“…Eleven percent of placebo subjects and 8% of alendronate subjects experienced fractures, which was not statistically different. Routine spine radiographs were not part of the study Bone 118 Alendronate vs premarin vs combination therapy vs placebo RCT Bone density of the lumbar spine was 6.0% greater with alendronate than with placebo, 6.0% greater for conjugated equine estrogens, and 8.3% greater for the combination; no difference in fracture rates 123 Etidronate Meta-analysis The pooled RR of vertebral fracture was 0.60% (95% CI 5 0.41-0.88), but no effect on nonvertebral fractures was seen Harris 124 Etidronate RCT BMD improved, but the risk of vertebral fractures was lower only for those at greater risk, defined as baseline BMD o50th percentile for the study group or three vertebral fractures Heath 125 Etidronate RCT Reduced rate of bone loss with etidronate Tanko 126 Ibandronate RCT 20 mg weekly dose of ibandronate significantly increased BMD at the spine and hip (4.0% and 2.7%, respectively, more than placebo) Chesnut 127 Ibandronate RCT Daily and intermittent oral ibandronate significantly reduced the risk of new vertebral fractures 62% and 50%, respectively, and improved BMD. The incidence of nonvertebral fractures was not different between the three groups Reid 128 Zoledronic acid RCT BMD improvement of the lumbar spine 4.3% to 5.1% compared with placebo (Po.001)…”